As far back as 2004 staff at LGC Group became convinced that Gyrolab® technology could fulfill two critical requirements in their work — small sample volumes and high throughput. Having acquired their first instrument in 2007, LGC became the first CRO to establish a GLP-validated method on Gyrolab platform. Rachel Green, Operations Director at LGC, explains: “Being able to run immunoassays at a nanoliter scale was a real asset, especially in pre-clinical studies where sample volumes are limited, making Gyrolab system the platform of choice. The other deciding factor was the high throughput of the system, which significantly increased our productivity.”
Andrew Roberts, Technical Director at LGC, was also impressed with the precision. “An early evaluation of Gyrolab system showed that of 180 samples run in duplicate, 80% had a CV less than 5%. This level of precision means that if we should ever choose to move to singlicate analysis then we would probably start on Gyrolab system.”
LGC’s sponsors see the benefits of using Gyrolab system for their assays, which has become well established in the industry, and LGC now has two Gyrolab instruments that gives the flexibility to run method development and sample analysis in parallel. Although the main application remains pharmacokinetic (PK) studies, analyzing a range of matrices including plasma, serum and synovial fluid, the bioanalytical team at LGC have utilized the ADA mixing CD application and are also investigating the use of Gyrolab affinity module, which is of increasing interest for their sponsors.
LGC main focus is on supporting clinical studies but have seen the advantages of using Gyrolab in pre-clinical studies. One project offered a real challenge — providing bioanalytical support for a 26-week toxicology study on a novel monoclonal antibody after the in-life phase had started. Gyrolab system was used to develop a method with a broad dynamic range in just four days, completed validation in less than two weeks, and delivered all the QC’d data for more than 5000 samples on time. More recently, two ongoing projects have encountered technical hurdles when run on other immunoassay platforms, and moving to Gyrolab system has resulted in more promising results. Andrew adds that Gyrolab system runs immunoassays in a different way compared to the standard sandwich assay. “Replacing periods of passive binding with short incubations and nanofluidics changes the paradigm of how the assays are working. Assays that don't work in a standard format can work in Gyrolab system, which has helped in a number of cases where ELISA has failed. Transferring to Gyrolab system can lead to a step change in performance.”
Rachel commented “The system’s flexibility is an advantage when developing immunogenicity assays. The automated nature of the system enables us to develop complex assays involving multiple reagent mixing steps within far shorter timeframes. Added to that, the chemistry of the column-capture format can offer improved drug- and target-tolerance in assays that are hitting technical road-blocks on other platforms.”
Backed by high performance technology, LGC Group takes pride in being able to offer their customers high levels of technical expertise, commitment, and responsiveness. Rachel adds, "A key part of being able to deliver is our supplier relationship. One of the major factors in choosing Gyrolab technology was the fact that we enjoy working with Gyros Protein Technologies, and we have developed a strong partnership with them over the years.” Andrew adds that, “The staff at Gyros Protein Technologies are great at reacting to client needs, both for instrument support and technical aspects of assay development. Having access to a third party that can look at things from a different angle is very valuable.”
Rachel sees the benefits for utilizing Gyrolab technology through much of the biopharma development pipeline. “The Gyrolab platform already plays a significant role in early discovery and development of biological drugs. The platform’s ability to run generic assays is invaluable when a drug candidate is being selected from a panel of monoclonal antibodies. The system plays a major role in the biosimilars market, where the clinical trial designs involve large sample numbers and short reporting timelines. The high throughput of Gyrolab system together with our experience, gives our customers confidence that LGC can support the analytical demands of phase II and phase III studies.”
Looking into the future, the bioanalytical team at LGC see Gyrolab system as their principle PK development tool and increasing a platform for ADA assays and will continue to use their expertise in Gyrolab technology to improve support to their sponsors.
As one of Europe’s largest dedicated bioanalytical centres and a recognised Protein LC-MS and Immunogenicity Centre of Excellence, we are industry leaders in providing integrated bioanalytical support across all phases of drug development and recognised for our leadership in science and technology.
Find out more at lgcgroup.com/DDS
You can find out more at LGCgroup.com/DDS